These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2134065)

  • 21. Effect of some novel synthetic analogues of CCK-4 on insulin and glucagon secretion.
    Khalid P; Chaturvedi S; Khan MM; Rastogi AK; Kundu B; Ahmad F; Mathur KB; Kidwai JR
    Acta Diabetol Lat; 1989; 26(3):203-9. PubMed ID: 2694715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of pseudo-peptide analogues of the C-terminal tetrapeptide of gastrin and evaluation of their biological activity on acid secretion.
    Rodriguez M; Bali JP; Magous R; Castro B; Martinez J
    Int J Pept Protein Res; 1986 Mar; 27(3):293-9. PubMed ID: 3011690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of analogues of the Des-Phe-NH2 C-terminal hexapeptide of cholecystokinin showing gastrin antagonist activity.
    Laur J; Rodriguez M; Aumelas A; Bali JP; Martinez J
    Int J Pept Protein Res; 1986 Apr; 27(4):386-93. PubMed ID: 3710694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation.
    Kolodziej SA; Nikiforovich GV; Skeean R; Lignon MF; Martinez J; Marshall GR
    J Med Chem; 1995 Jan; 38(1):137-49. PubMed ID: 7837225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secretin N-terminal hexapeptide potentiates insulin release in mouse islets.
    Kofod H
    Regul Pept; 1986 Oct; 15(3):229-37. PubMed ID: 3538223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells.
    Abdel-Wahab YH; O'Harte FP; Mooney MH; Conlon JM; Flatt PR
    Biochim Biophys Acta; 1999 Oct; 1452(1):60-7. PubMed ID: 10525160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of gastrin antagonists, analogues of the C-terminal tetrapeptide of gastrin, by introduction of a beta-homo residue.
    Rodriguez M; Fulcrand P; Laur J; Aumelas A; Bali JP; Martinez J
    J Med Chem; 1989 Mar; 32(3):522-8. PubMed ID: 2918498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of caerulein and pancreozymin on insulin secretion in normal subjects and in patients with insuloma.
    Fallucca F; Carratù R; Tamburrano G; Javicoli M; Menzinger G; Andreani D
    Horm Metab Res; 1972 Jan; 4(1):55. PubMed ID: 4551706
    [No Abstract]   [Full Text] [Related]  

  • 29. Conformational analysis of cholecystokinin CCK26-33 and related fragments by 1H NMR spectroscopy, fluorescence-transfer measurements, and calculations.
    Fournié-Zaluski MC; Belleney J; Lux B; Durieux C; Gérard D; Gacel G; Maigret B; Roques BP
    Biochemistry; 1986 Jul; 25(13):3778-87. PubMed ID: 3741836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible degradative process of cholecystokinin analogs in rabbit jejunum brush-border membrane vesicles.
    Su SF; Amidon GL; Lee HJ
    Life Sci; 2002 Nov; 72(1):35-47. PubMed ID: 12409143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins.
    Cosmatos A; Ferderigos N; Katsoyannis PG
    Int J Pept Protein Res; 1979; 14(5):457-71. PubMed ID: 395118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phe-Met-Arg-Phe-NH2 (FMRFa)-related peptides inhibit Na/Ca exchange in pancreatic B cells.
    Van Eylen F; Gourlet P; Vandermeers A; Lebrun P; Herchuelz A
    Adv Exp Med Biol; 1997; 426():223-5. PubMed ID: 9544278
    [No Abstract]   [Full Text] [Related]  

  • 33. Computational analysis of conformational behavior of cholecystokinin fragments. I-CCK4, CCK5, CCK6 and CCK7 molecules.
    Pattou D; Maigret B; Fournie-Zaluski MC; Roques BP
    Int J Pept Protein Res; 1991 May; 37(5):440-50. PubMed ID: 1917299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of cholecystokinin from the human brain.
    Miller LJ; Jardine I; Weissman E; Go VL; Speicher D
    J Neurochem; 1984 Sep; 43(3):835-40. PubMed ID: 6086839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of cholecystokinin on proinsulin gene expression in isolated mouse pancreatic islets.
    Lindskog S; Ahrén B; Malm D; Florholmen J
    Pancreas; 1996 Nov; 13(4):425-6. PubMed ID: 8899804
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor.
    Elshan NG; Jayasundera T; Weber CS; Lynch RM; Mash EA
    Bioorg Med Chem; 2015 Apr; 23(8):1841-8. PubMed ID: 25769518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicochemical determinants in hepatic extraction of small peptides.
    Hunter EB; Powers SP; Kost LJ; Pinon DI; Miller LJ; LaRusso NF
    Hepatology; 1990 Jul; 12(1):76-82. PubMed ID: 2373488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic spectrum of deseminopancreozymin octapeptide (proceedings)].
    Rönfanz M; Morgenstern E; Hagen A; Meineke G; Göres E
    Pharmazie; 1979; 34(5-6):346-7. PubMed ID: 515152
    [No Abstract]   [Full Text] [Related]  

  • 39. The isolation and characterization of an insulin-releasing tetrapeptide from urines of patients with lipoatrophic diabetes.
    Reichelt KL; Johansen JH; Titlestad K; Edminson PD
    Biochem Biophys Res Commun; 1984 Jul; 122(1):103-10. PubMed ID: 6378198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide.
    Khavinson VKh; Gapparov MM; Sharanova NE; Vasilyev AV; Ryzhak GA
    Bull Exp Biol Med; 2010 Sep; 149(3):351-3. PubMed ID: 21246099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.